UC Health News
CINCINNATI Researchers at the University of Cincinnati (UC) James L. Winkle College of Pharmacy and Cincinnati Childrens Hospital Medical Center have received a grant from the Department of Defense (DoD) to study pathways of drug delivery to pediatric brain tumorsspecifically pediatric brain tumors known as Diffuse Intrinsic Pontine Glioma (DIPG).
According to the National Institutes of Health, DIPG typically affects children 4 to 9 years of age. Children progressively lose muscle control as the tumor grows diffusely in the pons, which is a region deep inside the brain that connects the brain to the spinal cord. Due to its delicate and difficult to reach location, surgical removal is not an option, and radiation alone remains the standard of care. Despite radiation treatment, children usually succumb to the disease within nine months, and less than 1 percent survive longer than five years.
Recent advances in defining the genetic landscape of these tumors provides new hope, but obstacles remain for therapies.
“The field has made significant progress over the past decade in understanding the genetics that drive brain tumor development and growth. This provides an exciting opportunity to attack these tumors with new targeted therapies, but unfortunately, the vast majority of these drugs do not penetrate into the brain, says Timothy Phoenix, PhD, principal investigator on the three-year, $577,200 Career Development Grant.
At present, Phoenix says, toxic drugs often have to be given at very high doses in order to have any prospect of adequate amounts crossing the blood-brain barrier.
The study, titled “Defining and Targeting the Blood-Brain Barrier in Pediatric Glioma Subgroups, will provide a basic understanding of tumor-blood vessel interactions, and identify potential differences between brain tumors that grow in different locations. In addition, Phoenix will examine if manipulating blood vessel Wnt signaling, a regulator of vascular permeability and drug penetration he identified prior to coming to UC, will improve drug penetration …